PMID- 34719646
OWN - NLM
STAT- MEDLINE
DCOM- 20220210
LR  - 20220210
IS  - 1347-5215 (Electronic)
IS  - 0918-6158 (Linking)
VI  - 44
IP  - 11
DP  - 2021
TI  - Methylglyoxal-Derived Advanced Glycation End Products (AGE4) Promote Cell 
      Proliferation and Survival in Renal Cell Carcinoma Cells through the RAGE/Akt/ERK 
      Signaling Pathways.
PG  - 1697-1706
LID - 10.1248/bpb.b21-00382 [doi]
AB  - Advanced glycation end products (AGEs) are the products formed through a 
      non-enzymatic reaction of reducing sugars with proteins or lipids. There is a 
      potential for toxicity in the case of AGEs produced through glycation with 
      dicarbonyl compounds including methylglyoxal, glyoxal, and 3-deoxyglucosone. The 
      AGEs bind the receptor for advanced glycation end products (RAGE) and stimulate 
      the mitogen-activated protein (MAP) kinase signaling pathway that can increase 
      the production of matrix metalloproteinases (MMPs). In addition, AGE-induced 
      protein kinase B (Akt) signaling can promote cancer cell proliferation and 
      contribute to many diseases such as kidney cancer. In light of the lack of 
      extensive study of the relationship between methylglyoxal-induced AGEs (AGE4) and 
      renal cancer, we studied the proliferous and anti-apoptotic effects of AGE4 on 
      renal cell carcinoma (RCC) in this study. AGE4 treatment was involved in the 
      proliferation and migration of RCC cells in vitro by upregulating proliferating 
      cell nuclear antigen (PCNA) and MMPs while suppressing apoptotic markers such as 
      Bax and caspase 3. Moreover, Akt and extracellular-signal-regulated kinase (ERK) 
      were phosphorylated in RCC cells with AGE4 treatment. As a result, this study 
      demonstrated that AGE4-RAGE axis can promote the growth ability of RCC by 
      inducing PCNA, MMPs, and inhibiting apoptosis in RCC via the Akt and ERK 
      signaling pathways.
FAU - Nam, Han-Kyul
AU  - Nam HK
AD  - Department of Biotechnology, College of Life Sciences and Biotechnology, Korea 
      University.
FAU - Jeong, So-Ra
AU  - Jeong SR
AD  - Department of Biotechnology, College of Life Sciences and Biotechnology, Korea 
      University.
FAU - Pyo, Min Cheol
AU  - Pyo MC
AD  - Department of Biotechnology, College of Life Sciences and Biotechnology, Korea 
      University.
FAU - Ha, Sang-Keun
AU  - Ha SK
AD  - Division of Functional Food Research, Korea Food Research Institute.
FAU - Nam, Mi-Hyun
AU  - Nam MH
AD  - Sue Anschutz-Rodgers Eye Center and Department of Ophthalmology, University of 
      Colorado.
FAU - Lee, Kwang-Won
AU  - Lee KW
AD  - Department of Biotechnology, College of Life Sciences and Biotechnology, Korea 
      University.
LA  - eng
PT  - Journal Article
PL  - Japan
TA  - Biol Pharm Bull
JT  - Biological & pharmaceutical bulletin
JID - 9311984
RN  - 0 (Glycation End Products, Advanced)
RN  - 722KLD7415 (Pyruvaldehyde)
SB  - IM
MH  - Blotting, Western
MH  - Carcinoma, Renal Cell/*metabolism
MH  - Cell Cycle
MH  - Cell Line, Tumor
MH  - Cell Movement
MH  - *Cell Proliferation
MH  - *Cell Survival
MH  - Flow Cytometry
MH  - Glycation End Products, Advanced/metabolism/*pharmacology
MH  - Humans
MH  - Kidney Neoplasms/*metabolism
MH  - *MAP Kinase Signaling System
MH  - Pyruvaldehyde/pharmacology
MH  - Real-Time Polymerase Chain Reaction
OTO - NOTNLM
OT  - apoptosis
OT  - extracellular-signal-regulated kinase
OT  - proliferation
OT  - protein kinase B
OT  - receptor for advanced glycation end product
OT  - renal cell carcinoma
EDAT- 2021/11/02 06:00
MHDA- 2022/02/11 06:00
CRDT- 2021/11/01 06:00
PHST- 2021/11/01 06:00 [entrez]
PHST- 2021/11/02 06:00 [pubmed]
PHST- 2022/02/11 06:00 [medline]
AID - 10.1248/bpb.b21-00382 [doi]
PST - ppublish
SO  - Biol Pharm Bull. 2021;44(11):1697-1706. doi: 10.1248/bpb.b21-00382.